Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA060039-03
Application #
2100647
Study Section
Radiation Study Section (RAD)
Project Start
1994-07-20
Project End
1997-06-30
Budget Start
1996-07-01
Budget End
1997-06-30
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Name
Center for Molecular Medicine/Immunology
Department
Type
DUNS #
City
Belleville
State
NJ
Country
United States
Zip Code
07950
Stein, Rhona; Govindan, Serengulam V; Mattes, M Jules et al. (2003) Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res 63:111-8
Stein, R; Govindan, S V; Chen, S et al. (2001) Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. J Nucl Med 42:967-74
Stein, R; Govindan, S V; Chen, S et al. (2001) Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine. Crit Rev Oncol Hematol 39:173-80
Govindan, S V; Mattes, M J; Stein, R et al. (1999) Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids. Bioconjug Chem 10:231-40
Patel, S; Stein, R; Ong, G L et al. (1999) Enhancement of tumor-to-nontumor localization ratios by hepatocyte-directed blood clearance of antibodies labeled with certain residualizing radiolabels. J Nucl Med 40:1392-401
Stein, R; Govindan, S V; Mattes, M J et al. (1999) Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides. Clin Cancer Res 5:3079s-3087s
Blumenthal, R D; Sharkey, R M; Kashi, R et al. (1997) Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts. Tumour Biol 18:367-77
Stein, R; Goldenberg, D M; Thorpe, S R et al. (1997) Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung. J Nucl Med 38:391-5
Sharkey, R M; Behr, T M; Mattes, M J et al. (1997) Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 44:179-88
Stein, R; Chen, S; Haim, S et al. (1997) Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. Cancer 80:2636-41

Showing the most recent 10 out of 12 publications